Karyopharm provides u.s. regulatory update on selinexor in advanced or recurrent endometrial cancer

Newton, mass., march 1, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its discussions with the u.s. food and drug administration (fda) regarding its previously planned supplemental new drug application (snda) submission based on the data from the phase 3 siendo study evaluating selinexor as a front-line maintenance therapy following chemotherapy in patients with advanced or recurrent endometrial cancer.
KPTI Ratings Summary
KPTI Quant Ranking